SURPASS-CVOT: Cardiovascular outcomes with tirzepatide vs dulaglutide in type 2 diabetes with established ASCVD.

What else it found

• Tirzepatide met non-inferiority against an active comparator already proven to reduce cardiovascular events.
• Weight fell about 9 kg more and HbA1c about 0.4% more on tirzepatide.
• This gives tirzepatide its first large, long-duration cardiovascular safety dataset.

Safety and tolerability

Consistent with prior tirzepatide trials over more than four years of exposure.

Trial record

How to read this trial critically

Design: Double-blind. Comparator: Active. Endpoint type: clinical events. Funding: Eli Lilly and Company.

Estimands — which question the headline number answers

An event-driven outcome trial counts adjudicated clinical events rather than a biomarker, and runs until a target number of events accrues rather than to a fixed week. This is the highest grade of evidence in the library.

Discontinuation and what it means here

Long-duration outcome trials accumulate substantial discontinuation; the treatment-policy estimand is the appropriate lens because it counts everyone randomised.

Missing data

Vital status follow-up is pursued even for participants who stop treatment, which is what makes an outcome trial interpretable.

Sponsorship and conflicts of interest

Sponsor-funded event-driven cardiovascular outcome trial against an active comparator.

Who this result applies to

Adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It does not establish cardiovascular benefit in people with obesity and without diabetes.

Why a head-to-head result carries more weight than a cross-trial comparison

Comparing two drugs by lining up their separate placebo-controlled trials is unreliable: the populations, durations, endpoints and estimands differ, and those differences can move a result by several percentage points on their own. A randomized head-to-head removes that problem, which is why a direct comparison is worth more than any number of indirect ones.

What this trial cannot tell you

Every limitation below applies to SURPASS-CVOT as it applies to the rest of the program. None of them makes the result unreliable; all of them constrain how far it can be generalised to you.

• Trial participants receive the medication free, with structured follow-up and lifestyle support that most patients do not get. Real-world results are consistently smaller.
• Enrollment criteria exclude many people who would take the drug in practice, including some with significant comorbidity.
• Mean results conceal the distribution. A trial mean contains both strong responders and people who lost very little.
• Adverse events are collected under trial conditions, which detects some events better than routine care and others worse.
• These results were generated with the FDA-approved product. No compounded preparation has been tested in a trial of this kind.

How we use this trial on the rest of the site

Where a page on this site quotes a figure from SURPASS-CVOT, it names the trial, gives the dose the figure came from, and states the population. We do not present a single arm's result as though it applied to everyone, and we do not round a range into one dramatic number. If you find a page that does, tell us through the corrections process and we will fix it.

How to read the SURPASS-CVOT trial

SURPASS-CVOT is a Phase 3, randomized, double-blind, active-controlled non-inferiority; median follow-up ~4.3 years study. That design matters for how much weight the result carries: randomisation is what allows the difference between arms to be attributed to the drug rather than to the kind of person who chose it, and blinding is what stops expectation from moving subjective endpoints. Where a trial is open-label, treat patient-reported outcomes with more caution than objectively measured ones such as body weight or HbA1c.

What the primary endpoint does and does not tell you

The primary endpoint here was Time to first major adverse cardiovascular event (MACE-3). A primary endpoint is chosen before the trial starts and is the only result the study is properly powered to detect; everything else reported alongside it is secondary or exploratory and carries less weight, however striking the number looks. When a marketing page quotes a figure from a trial, the first question worth asking is whether that figure was the primary endpoint or something found further down the results table.

Who SURPASS-CVOT actually studied

Type 2 diabetes with established atherosclerotic cardiovascular disease — 13,299 adults participants. Trial populations are selected: they exclude many of the comorbidities, medications and circumstances that ordinary patients bring, and participants receive structured follow-up and free medication that real-world patients do not. That is the main reason real-world weight outcomes across this drug class run consistently below trial averages, and it is a reason to read the mean effect as a ceiling rather than a forecast.

SURPASS-CVOT reported harms and adverse events

Consistent with prior tirzepatide trials over more than four years of exposure. Adverse-event rates in trials are collected systematically, which makes them more reliable than anecdote but also means they capture mild events that patients might not otherwise report. Our side-effect reference puts these figures alongside the rest of the program.

Why SURPASS-CVOT matters

The most common criticism of tirzepatide versus semaglutide was thinner long-term outcome data. This trial closes most of that gap.

Reading the SURPASS-CVOT primary source

We summarize; we do not substitute. The registration record carries the pre-specified protocol, endpoints and eligibility criteria, and the published report carries the full results and limitations sections that summaries like this one necessarily compress. Both are linked in the sources below, and if our summary and the primary report disagree, the primary report is right — tell us through corrections and we will fix it.

SURPASS-CVOT: what a result like this can and cannot establish

A randomized trial establishes that a difference between arms is attributable to the intervention rather than to who chose it. It does not establish that you will experience the mean, that the effect persists beyond the observation window, or that it generalizes to people who would have been excluded from enrolment. Those three limits apply to every figure quoted from SURPASS-CVOT, including the ones quoted on this site.

Duration is the limit worth holding onto. A 72-week trial tells you what happened over 72 weeks. For a therapy that current evidence says should continue indefinitely, that is a short window, and honest reading treats the long-term profile as still accumulating rather than settled.

SURPASS-CVOT in the context of the wider program

No single trial carries a drug. SURPASS-CVOT sits alongside the rest of the program, and the weight of evidence comes from consistency across them rather than from any one headline. The most directly related studies indexed here:

• SURMOUNT-1 (2022) — Does tirzepatide cause weight loss in adults with obesity and without diabetes?
• SURMOUNT-5 (2025) — Head-to-head: tirzepatide vs semaglutide for weight loss in adults with obesity and without diabetes.
• SURMOUNT-4 (2024) — What happens if you stop tirzepatide after reaching a maintenance dose?

How marketing distorts SURPASS-CVOT

Three distortions recur. Quoting a secondary or exploratory endpoint as though it were the primary result. Quoting the completer or per-protocol figure rather than the intention-to-treat figure, which is higher and less representative. And quoting a trial mean as an individual forecast. When a program's landing page cites a percentage without naming the trial, the dose and the timepoint, all three of those are available to it.

What SURPASS-CVOT means for what you pay

Efficacy evidence attaches to the molecule, not to the vial it arrives in. The same tirzepatide studied here is dispensed by compounding pharmacies from $133 per month, and by the manufacturer as an FDA-approved product at a considerably higher price. What the higher price buys is regulatory review of that specific product, metered dosing and a manufacturer's quality system — not a different result in a trial like this one. Anyone claiming clinical superiority for a compounded preparation on the strength of SURPASS-CVOT is over-reading it, and so is anyone claiming a compounded preparation was proven equivalent by it.

SURPASS-CVOT: reading the record yourself

The registration record carries the pre-specified protocol, endpoints and eligibility criteria; the published report carries the full results and the limitations section that any summary compresses. Both are linked in the sources below. If our summary and the primary report conflict, the primary report governs and we would like to hear about it through corrections.

SURPASS-CVOT: statistics worth understanding before quoting it

Two conventions decide how large a trial result looks. The intention-to-treat analysis counts everyone randomized, including those who stopped early, and is the conservative and more honest figure. The completer or efficacy analysis counts only those who finished on treatment, and always looks better. Weight-loss trials in this class report both, and marketing predictably quotes the second. When a percentage appears without a stated analysis population, assume the flattering one.

The second convention is the confidence interval. A mean of twenty per cent with a wide interval and a mean of twenty per cent with a narrow one are different results, and only the interval tells you how precisely the effect was estimated. Neither appears in an advertisement.

SURPASS-CVOT: who is missing from it

Trial eligibility criteria exclude people, and the exclusions are systematic rather than random: severe comorbidity, certain concurrent medications, recent cardiovascular events, pregnancy, and frequently significant psychiatric or eating-disorder history. If you would have been excluded from this trial, its mean is a weaker guide for you than it is for someone who would have qualified — and your prescriber is the person who can say which of those you are.

SURPASS-CVOT: what would change the conclusion

Longer follow-up showing the effect attenuating. Outcome data showing the weight change does not translate into the clinical benefits it is assumed to produce. Or head-to-head evidence against a newer comparator reversing the ranking. None of those has happened, but naming them is what distinguishes reading evidence from repeating it — and it is why our evidence policy commits to updating rather than defending what we published.

SURPASS-CVOT: what patients get wrong most often

Four mistakes recur, and all four are expensive. Judging the drug on the first month, when the starter dose is not a treatment dose and a flat scale predicts nothing. Comparing programs on the advertised price, which describes four weeks of a twelve-month course. Treating a plateau as failure rather than as the expected shape of the trial curves. And stopping for cost without pricing the market first, when the spread between the cheapest and dearest route to the identical molecule runs from $133 to $399 a month at entry.

The fifth, less common but more serious, is buying outside the licensed channel because a price looked unbeatable. Research-labelled peptide sold without a prescription is a different market with no clinical oversight and no accountability if something goes wrong, and the disclaimer that it is not for human consumption exists so the seller can say you were told.

SURPASS-CVOT: the three-year view

Current evidence treats obesity pharmacotherapy as ongoing while it remains effective, tolerated and appropriate, and the withdrawal data show substantial regain after stopping. That makes three years a more honest planning horizon than twelve months. At the cheapest tracked route, holding a 10 mg maintenance dose for three years costs roughly $7,164; at the dearest compounded route it is several times that for the same molecule. Deciding on a first-month price is deciding on the least representative number available.

SURPASS-CVOT: what would change this page

New trial evidence, a change in the labelling, a shift in the compounding framework, or a correction from a reader. Clinical statements here follow the prescribing information and the published trial program; price figures carry a verification date and sit in a downloadable dataset. Where the evidence is genuinely limited — long-term data beyond the trial horizon, bioavailability of compounded oral preparations, the human relevance of the rodent thyroid finding — this site says so rather than filling the gap with confident language, and updates rather than defends when better evidence arrives.